Shares of Itamar Medical Ltd. (NASDAQ:ITMR) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $18.25 for the company, according to Zacks. Zacks has also assigned Itamar Medical an industry rank of 104 out of 256 based on the ratings given to its competitors.

Separately, LADENBURG THALM/SH SH began coverage on Itamar Medical in a research report on Tuesday, August 6th. They set a “buy” rating for the company.

Shares of NASDAQ:ITMR traded up $0.98 during trading on Friday, reaching $10.14. 200 shares of the company traded hands, compared to its average volume of 331. Itamar Medical has a 52 week low of $8.27 and a 52 week high of $14.00.

Itamar Medical Company Profile

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market in the United States and Canada, Europe, Israel, Japan, the Asia Pacific, and internationally. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities.

Featured Story: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Itamar Medical (ITMR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Itamar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itamar Medical and related companies with's FREE daily email newsletter.